Rosa: Ambulatory COVID-19 Patients Treated with Lactoferrin as a Supplementary Antiviral Agent: A Preliminary Study

Rosa, 121 patient lactoferrin early treatment study: 76% lower hospitalization [p=0.32], 40% slower recovery [p=0.5], and 39% faster viral clearance [p=0.02] https://c19p.org/rosa

copied to clipboard

Ambulatory COVID-19 Patients Treated with Lactoferrin as a Supplementary Antiviral Agent: A Preliminary Study

Rosa et al., Journal of Clinical Medicine, doi:10.3390/jcm10184276

21 Sep 2021 Source PDF Share Tweet

Retrospective survey based study in Italy with 82 patients treated with lactoferrin, and 39 control patients, showing significantly faster viral clearance with treatment. There was no significant difference in recovery time overall, however the treatment group had significantly more moderate condition patients (39% versus 8%), and improved recovery was seen with treatment as age increased. Median dose for asymptomatic patients was 400mg/day, for paucisymptomatic patients 600mg/day, and for moderate condition patients 1000mg three times a day.

Important missing comments or errors? Let us know.

risk of hospitalization, 75.6% lower, RR 0.24, p = 0.32, treatment 0 of 82 (0.0%), control 1 of 39 (2.6%), NNT 39, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).

recovery time, 40.0% higher, relative time 1.40, p = 0.50, treatment 82, control 39, excluded in exclusion analyses: excessive unadjusted differences between groups.

time to viral-, 39.4% lower, relative time 0.61, p = 0.02, treatment 82, control 39, inverted to make RR<1 favor treatment, Cox regression, primary outcome.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Rosa et al., 21 Sep 2021, retrospective, Italy, peer-reviewed, 8 authors, study period October 2020 - March 2021.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Lactoferrin All

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit